Projects
Treatment of Gait disorders in Dravet syndrome KU Leuven
This project seeks to improve the mobility and quality of life of patients with Dravet syndrome by developing a clinical framework for differential diagnosis of mobility problems in these patients.
Towards precision medicine for Dravet syndrome using personalized zebrafish disease models KU Leuven
Discovery of therapeutic targets and precision therapies for Dravet syndrome using a zebrafish disease model KU Leuven
Despite the availability of numerous antiseizure medications, about 30% of epilepsy patients still suffer from seizures due to drug-resistant epilepsy. Hence, we need to think beyond symptomatic treatment and develop precision therapies (i.e., anti-epileptogenic therapies and disease-modifying agents) that target hub genes and key pathways within epileptogenesis, the gradual process by which a brain develops epilepsy. It is thus essential to ...
Neurodevelopmental impact of epilepsy on autonomic function in Dravet Syndrome University of Antwerp
Genetics of Dravet syndrome – from genotype-phenotype correlations to disease modeling in zebrafish. University of Antwerp
Unraveling epileptogenesis in an iPSC-based zebrafish model of Dravet syndrome KU Leuven
Epileptogenesis is the process whereby a previously normal brain is functionally altered and biased towards generating spontaneous recurrent seizures. As 35% of epilepsy patients suffer from drug-resistant epilepsy (DRE), there is an outstanding need to advance our understanding of the mechanistic processes underlying epileptogenesis. The patient’s genetic background is crucial as causes of DRE are multifactorial and disease severity is ...
Do epimutations cause Dravet syndrome? An integrated methylome and transcriptome analysis approach. University of Antwerp
Therapeutic strategies for Dravet syndrome: upregulation of endogenous SCN1A and modulation of remodeling KU Leuven
Dravet syndrome (DS) is a progressive and devastating neurodevelopmental disorder of early childhood characterized by severe seizures, behavioral disturbances, and cognitive decline. Current therapies are often only partially effective at reducing seizure frequency and do not address the behavioral and cognitive aspects of the disorder. There is therefore an urgent medical need to develop more effective therapies for DS that target all ...